Do serum neural autoantibodies alone prove central nervous system pathogenicity?

In a 77-year-old man, a serum neural-autoantibody result should be interpreted as one element of a syndrome-based neurologic assessment, not as a stand-alone explanation for cognitive, psychiatric, seizure, or other neurologic symptoms.

Clinical interpretation

• A compatible—often subacute—neurologic or psychiatric phenotype, supportive MRI/EEG or inflammatory CSF findings, and exclusion of competing diagnoses determine whether antibody reactivity is clinically meaningful.
• Serum positivity is supportive rather than diagnostic, especially with low titres or a phenotype that does not fit the implicated antibody. In suspected autoimmune-encephalitis mimics, 62% of serum neuronal-antibody results were not confirmed by alternative assays. In another cohort, 61.8% of positive results were false positives, and 95.2% of these occurred with serum-only testing.

CSF and assay confirmation

• Paired serum–CSF testing can establish whether there is CNS-relevant immune activity. Antibody detection in CSF, CSF-restricted oligoclonal bands, and an elevated IgG index support intrathecal immune activation, although none is independently diagnostic.
• Specimen choice depends on antibody target: CSF is particularly informative for NMDAR, GAD65, and GFAP antibodies, whereas serum can be more sensitive for LGI1 and CASPR2. Unexpected, weak, or isolated serum results should be checked with validated cell-based testing and an orthogonal assay.
• Normal routine CSF does not rule out autoimmune encephalitis; one cohort found entirely normal routine CSF in 12.1% of cases.

Mechanistic and practical implications

• Serum-only reactivity may reflect nonspecific binding, systemic rather than intrathecal antibody production, or assay-related false positivity; it does not itself demonstrate antibody-mediated CNS injury.
• MRI, EEG, routine CSF studies, infectious testing, and reassessment for alternative causes complement antibody testing.

Bottom line

• Clinical correlation and targeted confirmatory evaluation—often paired CSF/serum testing—are well supported before attributing CNS disease or pathogenic significance to a serum neural-autoantibody finding alone.